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OBJECTIVE—In the treatment of diabetic patients, the long-
acting insulin analog insulin detemir is less prone to induce
weight gain than other insulin formulations. Assuming that
because of its pharmacologic properties, detemir displays stron-
ger central nervous anorexigenic efﬁcacy than human insulin, we
compared acute effects of human insulin and detemir on electro-
encephalography (EEG) measures and food intake.
RESEARCH DESIGN AND METHODS—Frontocortical EEG
direct current (DC) potentials were recorded in 15 healthy men
during two hyperinsulinemic-euglycemic clamps that included an
insulin bolus injection (human insulin, 17.75 mU/kg body wt;
detemir, 90 mU/kg body wt) followed by a steady 90-min infusion
(1.0 vs. 2.0 mU  kg
1  min
1). A higher dosage was chosen for
detemir to compensate for its delay in impact relative to human
insulin and to elicit similar systemic effects. At 20 min after
infusion, subjects were allowed to eat ad libitum from a test
buffet.
RESULTS—Mean glucose infusions to maintain euglycemia
(P  0.93) and blood glucose concentrations (P  0.34) did not
differ between conditions. Detemir infusion induced a negative
DC-potential shift, averaging 372.2 V from 21 to 90 min that
was not observed during human insulin infusion (146.5 V, P 
0.02). Detemir, in comparison with human insulin, reduced
subsequent food intake by 303 kcal (1,257 vs. 1,560, P  0.04).
CONCLUSIONS—While inducing comparable peripheral ef-
fects, detemir exerts stronger acute effects on brain functions
than human insulin and triggers a relative decrease in food
consumption, suggesting an enhanced anorexigenic impact of
detemir compared with human insulin on central nervous net-
works that control nutrient uptake. Diabetes 59:1101–1107,
2010
S
ystemic insulin accessing the brain via an active,
saturable transport mechanism (1) is assumed to
contribute to the central nervous regulation of
energy homeostasis (2). Experimental adminis-
tration of insulin to the central nervous system inhibits
food intake and reduces body fat content in animals (3,4)
and humans (5,6), suggesting that circulating insulin pro-
vides negative, anorexigenic feedback on the amount of
body fat to the brain. The long-acting insulin analog insulin
detemir, because of the acylation of a 14-carbon fatty acid
(myristic acid) to lysine at locus B29, displays increased
self-association and reversible albumin binding (7,8),
which delays absorption of the molecule and thereby
reduces the risk of hypoglycemic episodes (9,10). Insulin
therapy using detemir has been frequently found to induce
weight-sparing effects in comparison with other insulins,
curtailing body weight gain in patients with type 2 diabetes
(11,12) and maintaining stable body weight in type 1
diabetic patients (9,13,14). The mechanisms behind this
favorable effect of detemir are unclear. Because of its
pharmacologic properties, detemir might cross the blood-
brain barrier faster and in higher quantities than other
insulins and induce stronger effects on brain functions
(15,16). Supporting this assumption, detemir in compari-
son with human insulin has been found to amplify the
central nervous impact of hypoglycemia (16,17) and to
exert stronger magnetoencephalographic effects in over-
weight humans (15) who display relative central nervous
insulin resistance (18–20). To investigate the relevance of
enhanced central nervous detemir action in the regulation
of food intake, we assessed the effects of euglycemic
intravenous infusion of detemir in comparison with human
insulin on electroencephalography (EEG) direct current
(DC) potentials that are sensitive to changes in systemic
insulin concentrations (21) as well as on free-choice food
intake. As we aimed at comparing the brain impact of
peripherally equipotent doses of detemir and human insu-
lin, care was taken for both infusions to induce similar
effects on systemic glucose homeostasis.
RESEARCH DESIGN AND METHODS
Subjects and design. According to a single-blind, within-subject comparison,
15 healthy, normal-weight men (mean age  SE, 28.5  1.0 years; BMI, 23.1 
0.5 kg/m
2) participated in two hyperinsulinemic-euglycemic clamp experi-
ments (human insulin, detemir) spaced apart at least 1 week. The order of
conditions was balanced across subjects. All subjects gave written informed
consent to the experiments, which were approved by the local ethics
committee. In both experimental conditions, an insulin bolus injection (17.75
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diabetes.diabetesjournals.org DIABETES, VOL. 59, APRIL 2010 1101mU/kg body wt [ 0.1065 nmol/kg body wt] human insulin, Insulin Actrapid;
Novo Nordisk, Bagsværd, Denmark; 90 mU/kg body wt [ 2.16 nmol/kg body
wt] detemir, Insulin Levemir; Novo Nordisk) was given followed by a steady
90-min infusion of 1.0 mU  kg
1  min
1 ( 0.006 nmol  kg
1  min
1) human
insulin versus 2.0 mU  kg
1  min
1 ( 0.048 nmol  kg
1  min
1) detemir. To
compensate for the relatively slower onset of the action of detemir, a higher
dosage was chosen (15,17) to induce comparable peripheral effects of both
compounds as assessed by rates of glucose infusion necessary to keep blood
glucose levels in the euglycemic range.
Procedure. Volunteers reported to the laboratory at 0800, after an overnight
fast of 10 h, and were prepared for electroencephalographic recordings,
insulin infusions, and blood samplings. We inserted venous cannulas into the
subject’s arms and connected them to tubes enabling infusion and blood
sampling from an adjacent room without awareness of the subject. The arm
from which samples were taken was positioned in a heated box (55°C) to
enable drawing of arterialized venous blood. During recordings, subjects sat in
a reclining chair in a sound-attenuated room of constant temperature, with
their heads stabilized by a cushion. They were instructed to relax and not to
move during recordings and to ﬁxate their gaze on the wall in front of them.
Subjects pressed a button every estimated 30 s to maintain a constant state of
mental activity and to not doze off.
Recordings of DC potentials started at 0940 with a baseline phase of 20 min
followed by the bolus injection of human insulin and detemir, respectively
(t  0). Subsequent insulin infusion lasted for 90 min, ending at 1130 when
EEG recordings were also stopped. Arterialized blood was drawn at 15-min
intervals during baseline, at 5-min intervals during insulin infusion, and at
15-min intervals thereafter to monitor blood glucose concentration
(HemoCue B-Glucose-Analyzer, HemoCue AB, Angelholm, Sweden). During
and after insulin administration, subjects intravenously received a 20% glu-
cose solution at a variable rate to maintain normal plasma glucose levels.
Blood samples for the determination of hormonal parameters were repeatedly
collected, and routine assays were used to determine concentrations of serum
C-peptide, plasma ACTH, serum cortisol (all Immulite; DPC, Los Angeles, CA),
plasma glucagon (RIA; Adaltis, Montreal, Quebec, Canada), and serum leptin
(RIA; Linco Research, St. Charles, MO).
Food intake and mood assessment. At 1150 (i.e., 20 min after insulin
infusion had stopped), a standardized buffet of around 4,650 kcal was offered
from which subjects were allowed to eat ad libitum during the subsequent 50
min (Table 1). Subjects were kept unaware of hypothesized treatment effects
on food intake and were not aware that their food intake was measured by
weighing buffet components before and after food intake. In addition, to
prevent overeating, subjects were allowed to take with them any remaining
food afterward. Before (at 0915) and after (at 1135) recordings and at the end
of the session at 1300, subjects rated their hunger, thirst, and tiredness on
10-point scales and completed a questionnaire assessing alertness and auto-
nomic symptoms on 5-point bipolar scales of 20 contrasting adjective pairs
(e.g., activated-inert and sweating-shivery) (22). They also ﬁlled in a checklist
of 161 adjectives assessing mood on 14 dimensions (23).
Recordings. Standard recordings of DC potentials, electro-oculogram, and
electromyogram were performed as described previously (24,25). DC-poten-
tial recordings were obtained from left and right frontal (F3, F4), frontocentral
(FC3, FC4), and central (C3, C4) electrodes referenced to linked electrodes at
the mastoids. A BrainAmp DC ampliﬁer (Brain Vision, London, U.K.; low-pass
ﬁlter: 30 Hz, sampling rate: 200 Hz) was used. DC-potential drifts with
short-circuited input were constantly 5 V/h, and electrode impedance,
measured before and after recordings, never exceeded 5 k. Average DC-
potential values were determined ofﬂine for subsequent 5-s intervals. Linear
potential drifts during the 20-min baseline period extending into the 90-min
insulin infusion period were removed using a linear regression method.
Periods where electromyogram or electro-oculogram indicated increased
muscular activity or eye movements were excluded from analysis. The
average DC potential during baseline was set to 0 V, and potential shifts
during treatment were expressed as difference values.
Statistical analysis. Differences in DC-potential values between conditions
were evaluated ﬁrst on an exploratory basis by point-wise comparisons using
t tests to identify time ranges with most consistent differences (26). The time
range selected for analysis covered 21–90 min of insulin infusion. Values for
this time interval were then subjected to ANOVA, including the repeated-
measures factors Treatment (human insulin vs. detemir) and Topography
(electrode locations). Degrees of freedom were corrected using the Green-
house-Geisser procedure. Post hoc contrasts were used to specify signiﬁcant
ANOVA main effects and interactions. For the DC-potential analysis, data from
four subjects had to be excluded because of technical failures and artifacts of
apparent nonbiological origin. Behavioral measures and hormonal parameters
were analyzed with ANOVA and paired t tests as appropriate. P  0.05 was
considered signiﬁcant.
RESULTS
Glucose infusion rates, blood glucose, and hormonal
parameters. Rates of glucose infusion to maintain eugly-
cemia were similar between conditions (Fig. 1A; P  0.14
for all comparisons), resulting in identical total amounts of
energy supplied via glucose infusion (human insulin,
240.8  23.3 kcal; detemir, 239.5  25.0 kcal; P  0.93).
Correspondingly, blood glucose concentrations were com-
TABLE 1
Composition of the test buffet
Food Weight (g) Energy (kcal) Carbohydrate (g) Fat (g) Protein (g)
Bread rolls 300 719 153 4 8
Whole-grain bread 165 372 71 2 12
White bread 30 75 15 0.40 2
Butter 100 773 0.60 83 0.67
Jam 50 152 36 0.08 0.03
Honey 40 127 30 0 0.14
Hazelnut spread 40 142 30 0.32 3
Poultry sausage 40 75 0.13 4 8
Salami sausage 34 120 0.07 10 6
Semihard cheese 100 377 0.00 29 26
Spread cheese 33 87 0.63 8 3
Cream cheese 40 124 1 12 3
Fruit curd 150 173 23 4 9
Vanilla pudding 125 137 21 4 4
Apple 130 72 15 0.78 0.39
Banana 150 146 32 0.30 2
Whole milk 750 499 36 26 25
Strawberry milk 200 171 18 7 7
Orange juice 400 178 36 1 4
Condensed milk 30 34 3 1 2
Sugar 24 101 24 0 0
Total 4,654 545 197 125
Composition of the buffet offered 20 min after infusion of human insulin and insulin detemir, respectively, had been stopped and from which
subjects were allowed to eat ad libitum for 50 min. The buffet was served with coffee or tea. All values higher than 1 are rounded.
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all comparisons) as well as when restricting analysis to the
period of insulin infusion (P  0.13). Serum C-peptide
concentrations did not differ between conditions during
insulin infusion (P  0.25) but rose to slightly elevated
levels in the human insulin compared with the detemir
condition at the end of experiments (Fig. 1C; F[3,46] 
3.77, P  0.02 for Treatment 	 Time). Concentrations of
serum glucagon (Fig. 1D) as well as leptin did not differ
between conditions (all comparisons, P  0.40). Concen-
trations of plasma ACTH (P  0.57) and serum cortisol
(P  0.71) were likewise similar in both conditions, with
cortisol levels showing the expected meal-related increase
(F[3,47]  4.19, P  0.008).
Negative DC-potential shift during detemir infusion.
The DC potential in the detemir condition showed a
marked negative shift shortly after insulin injection that
reached maximum values exceeding 600 V toward the
end of the recording epoch (Fig. 2). This strong negative
DC shift was generally absent in the human insulin condi-
tion. Analyses of average DC-potential levels during the
relevant interval from 21 min after the start until the end of
insulin infusions conﬁrmed a distinctly more negative
potential level in the detemir than human insulin condition
(F[1,10]  7.03, P  0.02; Table 2), with this effect
displaying an even topographic distribution (F[2,24] 
0.59, P  0.59, for Treatment 	 Electrode location).
Comparisons with preinjection baseline levels conﬁrmed
signiﬁcance for the negative DC potential in the detemir
condition during 21–90 min of insulin infusion (F[1,10] 
8.53, P  0.02; F[3,27]  1.04, P  0.39 for Electrode
location). Although DC potentials in the human insulin
condition appeared to shift slightly toward positive values
over central positions, respective analyses did not yield
signiﬁcant differences from baseline values (F[1,10] 
0.17, P  0.43; Table 2).
Reduction of food intake by detemir in comparison
with human insulin. Table 3 summarizes treatment ef-
fects on food intake. Detemir in comparison with human
insulin signiﬁcantly reduced food consumption by 303 
135.7 kcal. Macronutrient comparisons suggested this ef-
fect was particularly pronounced for protein and, to a
lesser extent, for carbohydrate intake, but there was no
signiﬁcant statistical interaction between the factors
Treatment and Macronutrients (F[2,24]  1.63, P  0.22).
The reduction in total energy consumption and also car-
bohydrate intake by detemir in comparison with human
insulin was also observed in analyses taking into account
the energy received in the form of intravenous glucose
(Table 3). Differences in carbohydrate and protein intake
between conditions correlated signiﬁcantly with respec-
tive differences in DC-potential shifts (averaged over all
recording sites) from 21 to 90 min of infusions (r  0.74,
P  0.04, and r  0.87, P  0.01, respectively, bivariate
Pearson coefﬁcients). The respective correlation with total
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FIG. 1. A: Rates of glucose infused to maintain euglycemia and concentrations of (B) blood glucose, (C) serum C-peptide, and (D) serum glucagon
during intravenous infusion of human insulin (E) and insulin detemir (F), respectively. Infusions started with an insulin bolus injection (human
insulin, 17.75 mU/kg body wt; detemir, 90 mU/kg body wt) followed by a steady 90-min infusion (1.0 vs. 2.0 mU  kg
1  min
1). At 20 min after the
end of infusions, subjects ate ad libitum from a test buffet. *P < 0.05 for comparisons between conditions (t test). n  15.
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0.11; r  0.21, P  0.62 for fat intake).
Rating scales. Ten-point scale hunger ratings did not
differ between conditions, showing the expected decline
from baseline (detemir, 4.87  0.68; human insulin, 5.93 
0.54; P  0.11) and post-EEG recording values (5.87  0.62
vs. 5.93  0.56, P  0.91) to low postingestion levels
(1.47  0.43 vs. 1.00  0.24, P  0.33; P  0.12 for
F3 F4
FC3 FC4
C3 C4
** * * ** *
*********************
Insulininfusion
* * * ****** ** *****
*
* *** **
******************
** ******************
* ********* *** ** *
*
* ******************
**** *
-20 10 20 30 40 60 50 70 80
min
min
min min
-1000
-800
-600
-400
-200
0
200
400
µ
V
-10 0 -20 10 20 30 40 60 50 70 80
-1000
-800
-600
-400
-200
0
200
400
µ
V
-10 0
-20 10 20 30 40 60 50 70 80
-1000
-800
-600
-400
-200
0
200
400
µ
V
-10 0 -20 10 20 30 40 60 50 70 80
-1000
-800
-600
-400
-200
0
200
400
µ
V
-10 0
-20 10 20 30 40 60 50 70 80
-1000
-800
-600
-400
-200
0
200
400
µ
V
Insulin infusion
-10 0 -20 10 20 30 40 60 50 70 80
-1000
-800
-600
-400
-200
0
200
400
µ
V
-10 0
Time Time
Insulin infusion
Insulin infusion Insulin infusion
Insulin infusion Insulin infusion
min
min
FIG. 2. Average DC potentials recorded from left and right electrodes over frontal (F3, F4, respectively), frontocentral (FC3, FC4), and central
(C3, C4) cortical areas before and during intravenous infusion of human insulin (thin lines) and insulin detemir (bold lines), respectively.
Infusions started with an insulin bolus injection (human insulin, 17.75 mU/kg body wt; detemir, 90 mU/kg body wt) followed by a steady 90-min
infusion (1.0 vs. 2.0 mU  kg
1  min
1). In both conditions, euglycemia was maintained by infusion of glucose. The average potential during
baseline was set to 0 V. Rows of asterisks indicate signiﬁcance (P < 0.05; t tests) for point-wise comparisons of the potential levels between
conditions (upper row) and between the detemir condition and respective baseline levels (lower row). n  11.
TABLE 2
DC-potential levels during euglycemic infusion of human insulin and detemir
Site HI (mean  SE) Det (mean  SE)
HI vs. Det
(P value)
HI vs. baseline
(P value)
Det vs. baseline
(P value)
F3 7.19  168.77 470.24  148.92 0.06 0.97 0.01
FC3 211.28  243.76 343.87  169.76 0.13 0.41 0.07
C3 261.43  161.82 161.39  114.50 0.03 0.14 0.19
F4 61.82  224.03 426.24  179.60 0.25 0.79 0.04
FC4 213.07  239.50 406.36  139.26 0.01 0.39 0.02
C4 262.01  125.39 425.00  202.89 0.01 0.06 0.06
Average DC-potential levels (in V) over left and right frontal (F3, F4), frontocentral (FC3, FC4), and central (C3, C4) cortical areas from 21
to 90 min of intravenous infusion of human insulin (HI) and insulin detemir (Det), respectively. Plasma glucose levels were held constant by
additional glucose infusion. DC-potential values indicate differences from baseline (set to 0 V). The right three columns indicate signiﬁcance
for differences, respectively, between conditions and between the potential levels in the human insulin and detemir conditions and respective
baseline levels (t test; n 11). Bold indicates statistical signiﬁcance.
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icant differences between conditions was observed for
thirst (all P  0.12) and tiredness (P  0.33) ratings.
According to the bipolar questionnaire, subjects in the
detemir compared with the human insulin condition felt
more critical (critical-comfortable, 2.87  0.13 vs. 3.27 
0.18, P  0.009) and reported increased wakefulness
(sleepy-awake, 3.33  0.23 vs. 2.73  0.23, P  0.03) and
hunger (full-hungry, 4.20  0.20 vs. 3.53  0.22, P  0.01)
immediately after infusions. The remaining dimensions
and the post–food intake assessment were not affected.
The mood adjective checklist did not yield signiﬁcant
differences between conditions for any of the subscales.
DISCUSSION
Administration of insulin to the central nervous system
reduces food intake (3,5) and body weight (4,6). We
demonstrate that while eliciting comparable peripheral
effects, euglycemic infusion of insulin detemir compared
with human insulin triggers a distinct negative shift in EEG
DC-potential recordings and reduces calorie uptake in
healthy men, supporting our hypothesis that detemir af-
fects brain functions to a greater extent than human
insulin and induces stronger anorexigenic effects on cen-
tral nervous networks that control food intake. This out-
come suggests that enhanced catabolic insulin signaling to
the brain may be an important mechanism behind the
limitation of weight gain observed in diabetic patients
receiving detemir treatment (9,11–14).
In accordance with other investigators (15,17), we ad-
ministered insulin doses that were considerably higher in
the detemir than in the human insulin condition to com-
pensate for the delayed onset that human insulin–equimo-
lar detemir dosages would display. Accordingly, timing
and strength of the effects of detemir and human insulin on
systemic glucose homeostasis as reﬂected by the rates of
glucose infusion as well as blood glucose and serum
glucagon concentrations were identical. C-peptide concen-
trations likewise did not differ between conditions during
insulin infusion, merely showing a slight increase in the
human insulin condition after the test buffet that may have
been due to greater food intake in this compared with the
detemir condition. Congruent peripheral effects were also
indicated by comparable serum leptin concentrations that
are known to respond to insulin infusion (27,28).
On the background of equipotent systemic effects, det-
emir elicited a marked brain response as indicated by a
widespread negative shift of scalp-recorded DC potentials
that started around 15 min after detemir bolus injection
and exceeded potential levels in the control condition that
remained unaffected by human insulin infusion. In the
human insulin condition, subjects received roughly the
same total amount of insulin that, when administered in
single bolus form, induced a negative DC-potential shift in
foregoing experiments (21). Slowly infused over the
course of 90 min, this dose obviously was too weak a
stimulus to evoke DC-potential responses to human insu-
lin in the present experiments. In contrast, the 90-min
infusion of a detemir dose equivalent in terms of systemic
action triggered a sustained negative DC-potential shift
comparable with the previously reported effect of human
insulin administered in high-dose bolus form (21). This
pattern indicates that although central nervous detemir
effects may be mimicked by disproportionally high doses
of human insulin, the relative impact of detemir on brain
functions is considerably greater when both insulins are
administered at doses with similar peripheral impact.
The mechanisms behind the strong effect of detemir on
scalp-recorded DC potentials cannot be derived from our
data. Brain DC-potential shifts of this amplitude most
likely reﬂect changes in extracellular ionic concentrations
stemming from potential shifts at glial membranes that are
endowed with receptors for insulin and IGF (21,29–31).
The assumption of a widespread effect on cerebral cellular
networks also ﬁts with the global nature and long duration
of the DC-potential shifts induced by detemir infusion. Our
observations corroborate previous ﬁndings of increased
brain responses to detemir in comparison with human
insulin in animals (32) and humans (15–17). Superior
central nervous efﬁcacy of detemir may be due to im-
proved permeation of the lipophilic molecule into the
brain compartment, with enhanced receptor-mediated
blood-brain barrier transport of albumin-bound detemir
adding to this effect (15,32). The detemir-induced negative
DC-potential shift that is presumably of primary glial
origin thus may be reinforced by electrical potentials
generated in the course of receptor-mediated detemir
transport across the blood-brain barrier (33).
A most remarkable ﬁnding of our study is the reduction
of ad libitum food intake by around 300 kcal in the detemir
compared with the human insulin condition in the pres-
ence of identical peripheral actions of both insulins. This
pattern renders the contribution of systemic mediators to
this effect highly unlikely, rather suggesting that enhanced
TABLE 3
Food intake after euglycemic infusion of human insulin and detemir
Human insulin
(mean  SE)
Detemir
(mean  SE) P value
Total intake (kcal) 1,559.79  138.72 1,256.78  82.41 0.04
Carbohydrate (kcal) 803.18  50.59 630.14  49.76 0.06
Fat (kcal) 554.53  83.70 472.32  61.31 0.20
Protein (kcal) 202.09  20.40 154.32  13.41 0.004
Carbohydrate (% of total intake) 53.99  3.20 51.39  3.37 0.40
Fat (% of total intake) 33.19  2.91 36.25  3.24 0.32
Protein (% of total intake) 12.82  0.49 12.36  0.70 0.53
Total intake (including glucose infusion; kcal) 1,782.81  133.73 1,475.34  79.49 0.04
Carbohydrate (including glucose infusion; kcal) 1,026.20  54.28 848.69  52.50 0.05
Food intake from a test buffet of 4,650 kcal offered 20 min after infusion of human insulin and insulin detemir, respectively, had been stopped
and from which subjects were allowed to eat ad libitum for 50 min. Bottom lines indicate food consumption including the amount of energy
infused as glucose to maintain euglycemia until the end of the test buffet. Right column indicates signiﬁcance for differences between
conditions (t test; n  15). Bold indicates statistical signiﬁcance.
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resulted in decreased caloric intake. The concept of insu-
lin providing catabolic feedback on the body’s energy
resources to brain networks that control energy homeosta-
sis has been well established in animals (2,3) as well as in
humans (5,6). Thus, the decrease in food intake after
detemir compared with human insulin infusion suggests
that the enhanced effect on brain functions indicated by
the negative DC-potential shift particularly impacts the
central nervous control of food intake. Although because
of methodological constraints, DC-EEG could not be re-
corded during food intake proper (34), this interpretation
is supported by the strong correlation between the reduc-
tion in calorie intake and the antecedent DC-potential
effect elicited by detemir. It is also in line with animal
experiments in which intravenous detemir compared with
human insulin injections were associated with enhanced
insulin receptor phosphorylation in hypothalamic and
cerebrocortical tissue in conjunction with increased EEG-
assessed cortical activity, whereas the activation of the
insulin receptor signaling cascade was similar in muscle
tissue and liver (32). Interestingly, detemir compared with
human insulin infusion increased rather than decreased
self-rated hunger before test buffet presentation, which
may have been due to a biasing inﬂuence of enhanced
wakefulness and activation after detemir infusion (35).
Alternatively, this ﬁnding may also indicate that central
nervous insulin exerts its anorexigenic effects via meal-
related signals that contribute to the termination of a meal,
but not by affecting hunger motivation per se (5).
Weight gain is a frequent side effect when blood glucose
levels of diabetic patients are normalized by insulin
(36,37), but is less pronounced in patients undergoing
detemir therapy (9,11–14). The assumption that the use of
detemir limits weight gain because its favorable safety
proﬁle decreases defensive snacking to prevent hypogly-
cemia was not supported by comparative clinical studies
showing that insulin glargine, which like detemir reduces
the risk of hypoglycemia, is associated with greater weight
gain than detemir (38,39). Against this background, the
anorexigenic brain impact of detemir found in our study
rather suggests the contribution of central nervous mech-
anisms to the weight-sparing effect of detemir in the
clinical context.
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